Clinuvel gets green light

By Dylan Bushell-Embling
Wednesday, 11 June, 2008

Clinuvel Pharmaceuticals (ASX: CUV) has received ethical approval to begin Phase II testing of its solar urticaria (SU) treatment.

SU is a severe but rare disease that effects less than one per cent of the population. An SU sufferer's skin becomes badly sunburned after limited contact with the sun.

More prolonged exposure can cause red welts to appear on the skin, and can cause fainting, nausea and headaches. Symptoms last up to 24 hours.

Clinuvel hopes its new photo-receptive drug, CUV1647, can prove an effective preventative treatment for SU sufferers.

CUV1647 is expected to have a number of applications in the treatment of human diseases caused by abnormal quantities of melanin in the skin.

The trial will be conducted at Hope Hospital in Manchester in the UK.

Related News

ReCell proposal rated highly in the US

Avita Medical's cell suspension preparation device was this week the subject of two pieces of...

Refining respiratory disease diagnosis via smartphone

ResApp Health has enrolled its first patient at Princess Margaret Hospital, Perth, for a study...

R&D grant to accelerate Parkinson's treatment

Living Cell Technologies will receive a Callaghan Innovation R&D Growth Grant totalling an...

  • All content Copyright © 2015 Westwick-Farrow Pty Ltd